Immunic, Inc. presented new Phase 2 CALLIPER trial data showing that vidofludimus calcium sustains disability improvement in progressive multiple sclerosis (MS) patients during an open-label extension. Preclinical studies suggest the drug promotes neuronal survival via Nurr1 activation and reduces Epstein-Barr virus-related immune activity, linked to better cognitive function. Novel analyses also indicate the drug may improve disability outcomes more comprehensively than traditional measures. These findings support Immunic's planned Phase 3 trials in progressive and relapsing MS, with key results expected by the end of 2026.
Immunic's new clinical and preclinical data on vidofludimus calcium provide context for healthcare sector trends. For readers following healthcare stocks, here is Pluang's market snapshot as of Oct 21, 2026 18:11 WIB: out of 150 priced US health-sector stocks, 71 rose and 67 fell. Notable movers include TNGX at USD 26.20 (+3.76%), BAX at USD 25.30 (+3.22%), and NUVB at USD 4.91 (+2.94%).
The Human Feedback Foundation, supported by RBC, has launched the Agentic AI Design Exchange, a national program aimed at helping Canadian nonprofits design, build, and deploy AI agents responsibly. Funded through RBC's Stronger Nonprofits Program, t...
Satellos Bioscience Inc., a clinical-stage company focused on treatments for degenerative muscle diseases, announced its management will participate in two investor conferences in November: the Guggenheim Healthcare Innovation Conference on Nov 9 in ...
YYForce Inc. has purchased 20 wearable data collection systems to gather real task data from hotel room service at Novotel Singapore. This project aims to record and analyze experienced staff performing tasks like bed-making, towel folding, and clean...
The global digital health and remote patient monitoring market is projected to grow from $26.8 billion in 2025 to $80.8 billion by 2031, at a compound annual growth rate of 20.2%. This growth is driven by increasing demand for chronic disease managem...
The global private credit and alternative lending market, valued at $2.31 trillion in 2026, is expected to grow at a 7.8% CAGR to reach $3.36 trillion by 2031. Recent liquidity pressures in 2025, triggered by bankruptcies and AI sector concerns, caus...
